Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Radiation Syndrome
Biotechnology company responds to U.S. HHS Request for Information
January 25th, 2005
ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., (IRBO) recently responded to a Request for Information (RFI) from the U.S. Department of Health and Human Services (HHS) regarding potential therapeutics for the treatment for acute radiation syndrome (ARS). ImmuneRegen filed a formal response to the RFI respective to its compound Radilex, currently in development for treating the negative effects of toxic radiation exposure, including ARS. Recent testing of Radilex using Total Body Irradiation showed a 50% survival rate among irradiated mice treated with Radilex Post Lethal Exposure. Data...
Source: Life Science Weekly (2005-01-25)
|
